Browsing by Subject "Urokinase -- Therapeutic use"

Now showing items 1-3 of 3

Effect of Anthrax Lethal Toxin on Activation of MAPK Pathway and Autophagy in AML Cell Lines

Soukarieh, Rania (Lebanese American University, 2021-08-10)

Anthrax lethal toxin is an A-B toxin consisting of protective antigen (PrAg), the cell binding and translocation domain, and lethal factor (LF), the catalytic domain, which cleaves all mitogen-activated protein/extracellular ...
Sensitivity of acute myeloid leukemia cells to the dual targeting of the urokinase plasminogen activator and the MAPK pathway by a urokinase-activated anthrax lethal toxin. (c2013)

Bekdash, Amira (Lebanese American University, 2013-09-03)

Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by abnormal proliferation of myeloid progenitor cells. Around 15,000 new case of AML are diagnosed each year with a fatality rate of 65%. Conventional ...
Sensitivity of colorectal cancer cells to the recombinant Anthrax lethal toxin and the Urokinase-activated Anthrax lethal toxin. (c2014)

Kasbo, Zein Jean (Lebanese American University, 2015-02-26)

In this study, we attempt to simultaneously target the major hallmarks of colorectal cancer (CRC), the MAPK pathway and the urokinase plasminogen activator system using a dual-selective, Urokinase-activated, recombinant ...

Now showing items 1-3 of 3

Search LAUR